Compare ARK Autonomous Technology & Robotics ETF (ARKQ) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Autonomous Technology & Robotics ETF vs IDEXX Laboratories, Inc. — how do they compare? ARK Autonomous Technology & Robotics ETF trades at $122.9, while IDEXX Laboratories, Inc. trades at $563.59 (market cap $44.46B). The key difference: ARK Autonomous Technology & Robotics ETF is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| ARKQ | IDXX | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $143.82 | $766.68 |
52-Week Low | $91.86 | $514.61 |
Market Cap | — | $44.46B |
Enterprise Value | — | $45.36B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKQ trades at $123.99, down 0.57% with a bearish technical signal from moving averages. The ETF focuses on autonomous technology and robotics, benefiting from AI momentum with 57% gains since Q1 2026. Support levels cluster around $122-124 while resistance sits at $126-128. Recent news highlights China's EV targets and humanoid robotics growth projections reaching $200 billion by 2035.
The ETF shows strong momentum in AI and robotics themes but carries premium valuations with a 36x P/E ratio. Key risks include sector concentration and dependency on technological adoption rates. Institutional interest remains strong with $2.7 billion in assets, though technical indicators suggest near-term consolidation pressure.
IDXX trades at $563.57, up 0.89% today, with a bullish technical signal and strong fundamentals. The stock shows consistent earnings beats, with Q1 2026 EPS of $3.47 surpassing estimates. Revenue grew to $4.3B in 2025, with a robust net income margin of 24.63%. Analyst consensus is bullish with a $645 price target. Recent news highlights innovation in veterinary diagnostics and AI integration.
The outlook remains positive driven by earnings growth and market leadership, though high valuation multiples pose a risk. Key catalysts include upcoming Q2 2026 results and continued demand in pet healthcare. Risks involve competitive pressures and macroeconomic sensitivity. The stock offers growth potential but requires monitoring of valuation metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Autonomous Technology & Robotics ETF
ARKQ is an actively managed ETF that invests in autonomous technology and robotics. It focuses on disruptive innovations like autonomous mobility, electric vehicles, 3D printing, and energy storage, with holdings such as Tesla and Teradyne.
Read more on ARKQ →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
